Retrospective Study
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Sep 15, 2023; 14(9): 1385-1392
Published online Sep 15, 2023. doi: 10.4239/wjd.v14.i9.1385
Effects of paricalcitol combined with hemodiafiltration on bone-metabolism-related indexes in patients with diabetic nephropathy and chronic renal failure
Xiao-Ying Ma, Yu-Ping Sheng, Xing-Meng Yang, Hao-Ran Zhang, Fu-Yun Sun
Xiao-Ying Ma, Yu-Ping Sheng, Xing-Meng Yang, Hao-Ran Zhang, Fu-Yun Sun, Department of Nephrology, Cangzhou Central Hospital, Cangzhou 061000, Hebei Province, China
Author contributions: Ma XY designed and performed the research and wrote the paper; Sun FY designed the research and supervised the report; Sheng YP and Yang XM designed the research and contributed to the analysis; Zhang HR provided clinical advice.
Institutional review board statement: The study was reviewed and approved by the Cangzhou Central Hospital.
Informed consent statement: All participants have signed an informed consent form.
Conflict-of-interest statement: The authors declare no conflicts of interest for this article.
Data sharing statement: Clinical data for this study can be obtained from the corresponding author.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Fu-Yun Sun, MM, Professor, Department of Nephrology, Cangzhou Central Hospital, No. 16 Xinhua West Road, Yunhe District, Cangzhou 061000, Hebei Province, China. 17734498766@163.com
Received: May 4, 2023
Peer-review started: May 4, 2023
First decision: May 15, 2023
Revised: May 25, 2023
Accepted: August 7, 2023
Article in press: August 7, 2023
Published online: September 15, 2023
Processing time: 132 Days and 3.8 Hours
Abstract
BACKGROUND

Diabetic nephropathy (DN) is frequently seen in the development of diabetes mellitus, and its pathogenic factors are complicated. Its current treatment is controversial, and there is a lack of a relevant efficacy prediction model.

AIM

To determine the effects of paricalcitol combined with hemodiafiltration on bone-metabolism-related indexes in patients with DN and chronic renal failure (CRF), and to construct an efficacy prediction model.

METHODS

We retrospectively analyzed 422 patients with DN and CRF treated in Cangzhou Central Hospital between May 2020 and May 2022. We selected 94 patients who met the inclusion and exclusion criteria. Patients were assigned to a dialysis group (n = 45) and a joint group (n = 49) in relation to therapeutic regimen. The clinical efficacy of the two groups was compared after treatment. The changes in laboratory indexes after treatment were evaluated, and the two groups were compared for the incidence of adverse reactions. The predictive value of laboratory indexes on the clinical efficacy on patients was analyzed.

RESULTS

The dialysis group showed a notably worse improvement in clinical efficacy than the joint group (P = 0.017). After treatment, the joint group showed notably lower serum levels of serum creatinine, uric acid (UA) and blood urea nitrogen (BUN) than the dialysis group (P < 0.05). After treatment, the joint group had lower serum levels of phosphorus, procollagen type I amino-terminal propeptide (PINP) and intact parathyroid hormone than the dialysis group, but a higher calcium level (P < 0.001). Both groups had a similar incidence of adverse reactions (P > 0.05). According to least absolute shrinkage and selection operator regression analysis, UA, BUN, phosphorus and PINP were related to treatment efficacy. According to further comparison, the non-improvement group had higher risk scores than the improvement group (P < 0.0001), and the area under the curve of the risk score in efficacy prediction was 0.945.

CONCLUSION

For treatment of CRF and DN, combined paricalcitol and hemodiafiltration can deliver higher clinical efficacy and improve the bone metabolism of patients, with good safety.

Keywords: Paricalcitol; Hemodiafiltration; Diabetic nephropathy; Chronic renal failure; Serum calcium; Serum phosphorus; Intact Paricalcitol hormone

Core Tip: This study confirmed that paricalcitol combined with hemodiafiltration can effectively improve the condition of patients with diabetic nephropathy (DN) and chronic renal failure (CRF) and alleviate calcium–phosphorus metabolism disorder. This study has also successfully constructed a predictive model. It provides a new reference for evaluating the efficacy of treatment of combined DN and CRF.